<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508365</url>
  </required_header>
  <id_info>
    <org_study_id>CFD109701</org_study_id>
    <nct_id>NCT00508365</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives</brief_title>
  <official_title>A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, placebo-controlled, 2-session crossover
      study to evaluate the incidence of orthostatic hypotension in elderly hypertensive subjects
      following co-administration of carvedilol CR and lisinopril.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2007</start_date>
  <completion_date type="Actual">June 3, 2008</completion_date>
  <primary_completion_date type="Actual">June 3, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of orthostasis 6 hours post dose on day 1, 7, 8, 14 in each dosing session</measure>
    <time_frame>6 hours post dose on day 1, 7, 8, 14 in each dosing session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the incidence of orthostatic hypotension (defined as a decrease in SBP of ≥20 mmHg and/or a decrease in DBP of ≥10 mmHg in changing from the supine to the standing position) following co-administration of COREG CR and lisinopril</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship of concentration of drug to events 6 hours post dose on day 1, 7, 8, 14 in each dosing session</measure>
    <time_frame>6 hours post dose on day 1, 7, 8, 14 in each dosing session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of concentration of drug to events</measure>
    <time_frame>6 hours post dose on day 1, 7, 8, 14 in each dosing session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of the co-administration of COREG CR and lisinopril</measure>
    <time_frame>Up to Day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the relationship between the plasma concentrations of carvedilol and lisinopril and the occurrence of orthostatic hypotension following co-administration of COREG CR and lisinopril</measure>
    <time_frame>6 hours post dose on day 1, 7, 8, 14 in each dosing session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of COREG CR on plasma renin activity</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol CR capsules</intervention_name>
    <description>The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.</description>
    <arm_group_label>Subjects receiving treatment sequence BA</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence AB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules to match each dose level will be provided.</description>
    <arm_group_label>Subjects receiving treatment sequence BA</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence AB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Lisinopril will be available as 10 milligrams tablets administered orally once daily.</description>
    <arm_group_label>Subjects receiving treatment sequence BA</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence AB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females who are ≥ 65 years of age

          -  Body mass index (BMI) between 24 and 37 kg/m2 where: BMI = (weight in kg)/ (height in
             meters)2

          -  Subjects must have a documented history of essential hypertension and must be stable
             on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin
             antagonist and no more than one other antihypertensive medication at least 3 months
             before screening with a sitting SBP&lt;180 mmHg and DBP&lt;110 mmHg.

          -  All subjects must be able to be safely (in the opinion of the Investigator) withdrawn
             or down-titrated from all antihypertensive treatment(s) and transitioned to lisinopril
             10 mg OD for the two-week run-in phase.

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified on the screening history, physical or
             laboratory examination, or any other medical condition or circumstance making the
             volunteer unsuitable for participation in the study

          -  Subject who metabolizes carvedilol poorly based on CYP2D6 genotype as determined at
             screening

          -  Subject has persistent hyperkalemia or history of hyperkalemia resulting from either
             Type IV RTA (renal tubular acidosis) or previous treatment with an ACE inhibitor, ARB
             or renin inhibitor.

          -  Subject has malignant (accelerated) hypertension, history of malignant hypertension,
             or history of secondary forms of hypertension

          -  Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV)

          -  Subject has a history of hepatic impairment (characterized by prolonged prothrombin
             time/low concentrations of albumin) and/or renal insufficiency (subjects with an
             estimated CrCl ≤ 30 mL/min by Cockroft-Gault must be excluded). CrCL =
             [140-ageCr][weight/70] x 0.85 (if female); Cr in mg/dL; Weight in kg

          -  Subject is being treated for diabetes mellitus

          -  Subject has a history of angioedema

          -  Subject has been under treatment with 3 or more antihypertensive medications. (NOTE: A
             combination drug containing two antihypertensive agents represents two
             antihypertensive medications.)

          -  Subject has been under treatment with HCTZ &gt; 12.5 mg/day

          -  Subject is receiving ongoing treatment or is anticipated to receive treatment with any
             of the following medications during the study:

               -  monoamine oxidase inhibitors (MAO)

               -  any Class I or III antiarrhythmic

               -  alpha-adrenergic receptor blockers

               -  beta-2-adrenergic agonists

               -  all antidepressants including SSRIs

               -  lithium

               -  medications known to be inhibitors/inducers of cytochrome P-450 2D6 should be
                  discontinued for at least 14 days or 5 half-lives [which ever is longer] prior to
                  the first day of the run-in period

          -  Treatment with any over-the-counter medications , herbal and dietary supplements, as
             well as grapefruit-containing products within 7 days or 5 half-lives (whichever is
             longer) prior to first day of run-in period through the end of the study unless
             approved by the PI and GSK medical monitor. Standard vitamins and/or daily
             multi-vitamins are permitted, however herbal vitamins should be excluded.

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding the run-in period

          -  Subject has mean sitting SBP ≥ 180 mmHg at the screening assessment (one set of repeat
             measurement is permitted as per approval by the medical monitor).

          -  Documented history of low blood pressure within six months of screening visit (average
             sitting SBP &lt; 110 mm Hg and/or DBP /&lt; 50 mm Hg) or blood pressure below these values
             at time of screening (one set of repeat measurement is permitted as per approval by
             the medical monitor).

          -  Orthostatic hypotension diagnosed at screening (orthostatic hypotension is defined as
             a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in
             diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements)

          -  Subject has any of the following conditions:

               -  uncontrollable or symptomatic arrhythmias; unstable angina

               -  sick sinus syndrome or second or third degree heart block (unless treated with a
                  permanent, functioning pacemaker)

               -  bradycardia (seated heart rate &lt;55 bpm) (one repeat measurement is permitted as
                  per approval by the medical monitor) ; history of myocardial infarction, or
                  history of stroke within 1 year of screening.

               -  subject is in, or has a history of atrial fibrillation

          -  Any of the following abnormalities on 12-lead ECG during screening:

               -  complete RBBB or LBBB

               -  evidence of second- or third-degree AV block

               -  pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5
                  mV)

               -  any other abnormalities that investigator feels could be of concern when patient
                  is taking a β-adrenergic blocking agent

          -  Donation of blood in excess of 500 mL within a 56-day period including the estimated
             150 mL of blood to be drawn during this study

          -  History of asthma, COPD and/or hypersensitivity to β -adrenergic blocking agents

          -  History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE
             inhibitors

          -  History of sensitivity to any of the study medications or components thereof

          -  History of anaphylaxis or anaphylactoid reactions or severe allergic responses to
             drugs

          -  History of regular alcohol consumption exceeding 7 drinks/week for women or 14
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of
             hard liquor) within 6 months of screening

          -  Unanticipated positive urine drug screen (UDS) at screening. Note: If the subject is
             taking a drug known to give a positive on the UDS, then this should be discussed with
             the medical monitor prior to sending the UDS. In this situation, with prior approval,
             a positive finding on the UDS will not be considered an exclusion

          -  Positive for Hepatitis B surface antigen or HIV

          -  Unwillingness or inability to follow the procedures outlined in the protocol or
             inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/CFD109701?search=study&amp;study_ids=CFD109701#rs</url>
    <description>Results for study CFD109701 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lisinopril</keyword>
  <keyword>carvedilol</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD109701</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

